In our first post addressing government intervention into drug pricing, we gave a brief overview of commonly proposed tactics originating from the United States Department of Health and Human Services (HHS) and Congress. In this post, we discuss different approaches that aim to incite competition...
The issue of prescription drugs costs in the United States has incited legislative and judicial action. Between congressional hearings focused on insulin pricing and a ruling to block drug prices in TV advertisements, there have been significant developments this year alone. Proposals with the potential...
Herspiegel Consulting expands market access support for clients. We are excited to announce that we are expanding market access services and staff to meet our clients’ demand for strategic and tactical support in navigating the complex and dynamic network of payers, providers, intermediaries and influencers...
CREATES Act The CREATES Act hopes to spur generic competition in the pharmaceutical market. There are not many issues that receive bipartisan support from politicians in the United States, but there is one area where politicians appear willing to work together: drug prices. In February 2019, The...
Cigna’s Initiative to Lower the Out-Of-Pocket Cost of Insulin Due to public pressure, the health insurance giant, Cigna, has announced they will lower the monthly out of pocket cost of insulin for participating patients from an average of $40 to no more than $25. This plan,...
Happy Women’s Day! International Women’s Day is a global day to celebrate the social, economic, cultural, and political achievements of women. We are fortunate to have many hard working, high achieving women on our team, and we know that Herspiegel is stronger for their contributions....
Louisiana seeks “Netflix model” for hepatitis C drug pricing In January 2019, the Louisiana Department of Health sent out a solicitation seeking a pharmaceutical manufacturer partner on a so-called “Netflix pricing model” for hepatitis C treatment. Evoking the name of the technology giant has drawn a...
Unlike generics and biosimilars, 505(b)2 regulatory products likely involve a unique claim. While 505(b)2 asset approval relies on reference product core clinical program data, ideal 505(b)2 candidates can include: Drugs with new indications Drugs with changes in dosage form, strength, formulation, dosing regimen or route...
The impact of drug shortages is not new within the healthcare system, particularly at the hospital level, nor is the cost of drugs, however Fed Up with Drug Companies, Hospitals Decide to Start Their Own highlights a potential solution . The American Society of Health-System...
Citizen petitions have historically been a tool in the brand manufacturer’s toolkit of “product lifecycle management” but are fast becoming obsolete options due to mounting FDA resistance. A recent example of this came on January 5, 2018 when the FDA denied a citizen petition from...
